Prostate cancer is one of the most common cancers affecting men worldwide, with a high survival rate when detected early1 . Treatment decisions depend on the cancer's stage, grade, and patient health, with options ranging from active surveillance to surgery, radiation, and systemic therapies2 . Advances in diagnostic testing and personalized medicine continue to improve outcomes and help tailor treatments to individual risk profiles3 .
Active Surveillance and Monitoring
Active surveillance is a management strategy for low-risk, localized prostate cancer that involves close monitoring without immediate treatment4 . This approach is suitable for cancers expected to grow slowly and not cause symptoms, helping to avoid the side effects of overtreatment4 . Low-risk prostate cancer typically presents as localized tumors with prostate-specific antigen (PSA) levels under 10 ng/mL and a low Gleason score4 5.
During active surveillance, patients undergo regular clinical evaluations including PSA testing and digital rectal exams (DRE) approximately twice a year4 5. Imaging studies such as ultrasound or multiparametric MRI may be performed every 1–3 years to detect any changes in the tumor4 6. Repeat prostate biopsies are usually scheduled every 1–3 years to assess cancer progression5 7. If tests indicate tumor growth or spread, curative treatment is recommended7 .
Watchful waiting differs from active surveillance by using less intensive monitoring and focusing on symptom management rather than routine testing. It is generally reserved for older patients or those with other serious health issues unlikely to benefit from curative treatment4 5.
Patients considering active surveillance should maintain a healthy lifestyle, including regular exercise and a diet low in red meat and sugars, which may reduce the risk of cancer progression3 7.
- Key components of active surveillance include:
- PSA testing every 3–6 months7
- Annual digital rectal examination7
- Prostate MRI every 2–3 years7
- Confirmatory biopsy within 6–24 months of diagnosis7
- Repeat biopsies every 1–5 years based on clinical findings7
Prostate Cancer Surgery Options
Surgery remains a cornerstone for treating localized prostate cancer, aiming to remove the cancerous prostate gland and surrounding tissues8 9. The choice of surgical technique depends on cancer stage, patient health, and surgeon expertise9 .
Radical (Open) Prostatectomy
Radical prostatectomy involves the removal of the entire prostate gland, often including seminal vesicles and pelvic lymph nodes to ensure complete cancer excision8 9. The seminal vesicles contribute seminal fluid, and pelvic lymph nodes filter lymph and may harbor cancer spread4 8. Open radical prostatectomy requires an abdominal incision from the navel to the pubic area8 .
Potential side effects include urinary incontinence, sexual dysfunction, and changes in penile length8 . While orgasm may remain intact, ejaculation typically ceases after surgery9 . Many patients recover from complications over time, but some may experience lasting effects8 9.
Laparoscopic or Robotic Prostatectomy
Minimally invasive techniques such as laparoscopic or robot-assisted prostatectomy use small abdominal incisions and robotic instruments to remove the prostate10 . These approaches offer benefits including reduced pain, shorter hospital stays, and quicker recovery compared to open surgery10 . Robotic prostatectomy is now the most common surgical method for prostate cancer in many centers10 .
Transurethral Resection of the Prostate (TURP)
TURP is primarily a palliative procedure rather than curative, used to relieve urinary symptoms caused by prostate enlargement or obstruction2 . It involves removing prostate tissue through the urethra using a resectoscope. TURP does not remove the entire prostate and is not a treatment for prostate cancer itself but may be used to improve quality of life in selected patients2 .
Radiation Therapy for Prostate Cancer
Radiation therapy uses ionizing radiation to destroy prostate cancer cells and is effective for localized and locally advanced disease11 8. It can be delivered alone or combined with hormone therapy to improve outcomes8 .
External-Beam Radiation Therapy
External-beam radiation therapy (EBRT) directs high-energy rays at the prostate from outside the body8 . Treatment is typically administered daily on weekdays over several weeks, with each session lasting only minutes, though setup time may be longer11 8. EBRT is used to treat localized cancer and to palliate symptoms from bone metastases11 .
Side effects of EBRT often include urinary irritation, increased frequency, and gastrointestinal symptoms such as rectal discomfort and bleeding11 8. These side effects are usually temporary and manageable11 .
Brachytherapy
Brachytherapy involves placing radioactive sources directly into or near the prostate tumor, delivering high doses of radiation locally while sparing surrounding tissues11 . This internal radiation can be used alone or in combination with EBRT for certain patients8 . Side effects are similar to EBRT but may vary depending on the radiation dose and technique8 .
Focal Therapies for Localized Cancer
Focal therapies aim to treat localized prostate tumors with less morbidity than traditional surgery or radiation, targeting cancer cells while preserving healthy prostate tissue12 .
Cryotherapy
Cryotherapy destroys prostate tumors by freezing the tissue using needle probes guided by transrectal ultrasound (TRUS) inserted through the perineum12 . Cold gases circulate through the probes to induce tumor cell death12 . Side effects may include hematuria (blood in urine), pelvic pain, urinary frequency, and incontinence, which often improve over time12 . Nerve injury during cryotherapy can lead to erectile dysfunction12 .
High-Intensity Focused Ultrasound
High-intensity focused ultrasound (HIFU) ablates prostate tumors by delivering focused ultrasound waves that generate thermal energy to destroy cancer cells12 . While HIFU is less invasive and may preserve more healthy tissue, its effectiveness compared to conventional treatments is still under evaluation12 . Patients may choose HIFU as an option to reduce side effects12 .
Hormone Therapy for Prostate Cancer
Hormone therapy, or androgen deprivation therapy (ADT), reduces androgen levels, primarily testosterone, which fuels prostate cancer cell growth8 . ADT can cause tumor regression or halt progression by depriving cancer cells of hormonal stimulation8 .
Methods of ADT include:
- Orchiectomy: surgical removal of the testes, permanently eliminating testosterone production8 .
- LHRH (luteinizing hormone-releasing hormone) agonists: monthly or biannual injections or implants that suppress testicular testosterone production8 .
- LHRH antagonists: rapidly lower testosterone by blocking receptors, administered monthly by injection or daily orally8 .
Side effects of hormone therapy include sexual dysfunction, hot flashes, fatigue, and changes in body composition. Many side effects resolve after treatment cessation8 .
Recent advances include combining ADT with androgen receptor pathway inhibitors (ARPIs) such as abiraterone, enzalutamide, apalutamide, and darolutamide, which improve survival in metastatic hormone-sensitive prostate cancer13 .
“Triplet therapy increases survival in metastatic castration-sensitive prostate cancer. Early treatment intensification with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPIs) and docetaxel has changed the treatment paradigm.”
— Sandy Srinivas, Stanford Cancer Institute14
Chemotherapy for Advanced Prostate Cancer
Chemotherapy uses cytotoxic drugs to kill cancer cells systemically and is primarily reserved for metastatic or castration-resistant prostate cancer8 . Common agents include docetaxel and cabazitaxel8 .
Chemotherapy is given in cycles alternating treatment and recovery phases, mostly via intravenous infusion, with some oral options available8 . Side effects depend on the regimen and patient factors and may include fatigue, mucositis, gastrointestinal symptoms, and bleeding8 . Some side effects may persist long-term, but supportive medications can help alleviate adverse effects8 .
Chemotherapy can prolong survival and control disease progression but is not curative8 .
Immunotherapy Treatment Approaches
Immunotherapy enhances the immune system's ability to recognize and attack prostate cancer cells15 . Sipuleucel-T is an FDA-approved immunotherapy vaccine for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer15 . It improves survival without significantly affecting tumor size or PSA levels15 .
Sipuleucel-T is personalized by incubating a patient's immune cells with a prostate antigen fusion protein and administered as three infusions spaced about two weeks apart15 .
Emerging immunotherapies include bispecific antibodies that bind both cancer cells and immune cells, bringing them together to enhance immune attack on tumors16 .
Targeted Therapy for Prostate Cancer
Targeted therapies selectively inhibit molecular pathways critical for cancer cell survival, sparing normal tissues17 . PARP inhibitors, such as olaparib and rucaparib, impair DNA repair mechanisms in cancer cells, leading to cell death17 . These agents are indicated for metastatic prostate cancer patients with BRCA mutations after other therapies have failed17 .
Theranostics has changed how we treat patients with more advanced disease. We now have therapeutics specific for those with widespread metastatic disease identified by PSMA imaging.
Common side effects of PARP inhibitors include musculoskeletal pain, anemia, and gastrointestinal symptoms17 .
Clinical Trials for Prostate Cancer
Clinical trials evaluate novel therapies and treatment strategies, offering patients access to experimental treatments before approval18 . They are especially important for patients with refractory or advanced disease18 . Healthcare providers assist in identifying suitable trials, helping patients make informed decisions18 .
Participation in clinical trials can provide options beyond standard care and contribute to advancing prostate cancer treatment18 .
💡 Did You Know?
Genomic tests analyze the DNA of prostate cancer cells to better predict the risk of aggressive disease, helping guide treatment decisions3 .
Living With Prostate Cancer Management
Prostate cancer diagnosis and treatment impact physical, emotional, and social well-being4 . Patients often experience fear, anxiety, and concerns about health, finances, family, and work4 . Support from social and professional networks improves coping and quality of life4 .
Five-year survival rates for prostate cancer approach 97%, with nearly 100% survival for early-stage disease4 . Support services are available to help manage symptoms, emotional challenges, and financial burdens4 .
Patients are encouraged to discuss emotional and symptom management resources with their care team. Support may include peer groups, financial aid, and medications for symptom control4 .
“Our team includes urologists, radiation oncologists, nuclear medicine scientists, and basic scientists. I’m proud to be part of this multidisciplinary team caring for prostate cancer patients.”
— Sandy Srinivas, Stanford Cancer Institute14
Prostate Cancer Treatment Summary
Treatment for prostate cancer is individualized based on cancer characteristics and patient factors8 . Options include:
| Treatment Modality | Indication | Key Features | Side Effects |
|---|---|---|---|
| Active Surveillance | Low-risk, localized | Monitoring with PSA, biopsy, imaging | Minimal, avoids overtreatment |
| Surgery (Prostatectomy) | Localized prostate cancer | Removal of prostate ± seminal vesicles | Urinary incontinence, sexual changes |
| Radiation Therapy | Localized or locally advanced | External beam or brachytherapy | Urinary, bowel symptoms |
| Hormone Therapy (ADT) | Advanced/metastatic | Testosterone suppression | Sexual dysfunction, hot flashes |
| Chemotherapy | Metastatic, castration-resistant | Cytotoxic drugs (e.g., docetaxel) | Fatigue, nausea, mucositis |
| Immunotherapy | Advanced, hormone-resistant | Sipuleucel-T vaccine | Infusion reactions |
| Targeted Therapy | BRCA-mutated metastatic cancer | PARP inhibitors (e.g., olaparib) | Anemia, joint pain |
| Sources: 234 | |||
Choosing the right treatment involves weighing benefits against risks and side effects, considering patient preferences, and consulting a multidisciplinary care team2 19.
